Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit You

Showing results (41-50 of 141) with videos related to

Pageof 15
Sort By:
Bulletin Du Cancer|May 21, 2022
[hPG<sub>80</sub> and cancer: A new blood biomarker in development for patient monitoring]Benoit You, Eric Assenat, Léa Payen, et al.
Gynecologic Oncology|June 12, 2018
First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceivePierre-Adrien Bolze, Mélodie Mathe, Touria Hajri, et al.
JNCI Cancer Spectrum|June 30, 2020
Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)Olivier Colomban, Michel Tod, Julien Peron, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patientsBarnabe Bouvarel, Oliver Colomban, Jean-Sebastien Frenel, et al.
Annals of Surgical Oncology|October 29, 2021
Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort StudyVahan Kepenekian, Julien Péron, Benoit You, et al.
Critical Reviews in Oncology/Hematology|February 2, 2015
Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trialsFlorence Ranchon, Thierry Vial, Catherine Rioufol, et al.
Expert Review of Anticancer Therapy|May 18, 2023
Management of trophoblastic tumors : review of evidence, current practice, and future directionsAntoine Deleuze, Christophe Massard, Fanny Le Du, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 19, 2024
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patientsBarnabe Bouvarel, Oliver Colomban, Jean-Sebastien Frenel, et al.
Annals of Surgical Oncology|February 2, 2023
Comparison of Neoadjuvant Systemic Chemotherapy Protocols for the Curative-Intent Management of Peritoneal Metastases from Colorectal Cancer, Regarding Morphological Response, Pathological Response, and Long-Term Outcomes: A Retrospective StudyFlorian Fanget, Amaniel Kefleyesus, Julien Peron, et al.
Clinical Nuclear Medicine|May 23, 2024
Estimated Fetal Radiation Dose From 18 F-FDG PET/CT During the Second and Third Trimesters of PregnancyLaure Al Mansour, Perrine Tylski, Gautier Chene, et al.
Pageof 15

Showing results (41-50 of 141) with videos related to

Sort By:
Pageof 15
Bulletin Du Cancer|May 21, 2022
[hPG<sub>80</sub> and cancer: A new blood biomarker in development for patient monitoring]Benoit You, Eric Assenat, Léa Payen, et al.
Gynecologic Oncology|June 12, 2018
First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceivePierre-Adrien Bolze, Mélodie Mathe, Touria Hajri, et al.
JNCI Cancer Spectrum|June 30, 2020
Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)Olivier Colomban, Michel Tod, Julien Peron, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patientsBarnabe Bouvarel, Oliver Colomban, Jean-Sebastien Frenel, et al.
Annals of Surgical Oncology|October 29, 2021
Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort StudyVahan Kepenekian, Julien Péron, Benoit You, et al.
Critical Reviews in Oncology/Hematology|February 2, 2015
Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trialsFlorence Ranchon, Thierry Vial, Catherine Rioufol, et al.
Expert Review of Anticancer Therapy|May 18, 2023
Management of trophoblastic tumors : review of evidence, current practice, and future directionsAntoine Deleuze, Christophe Massard, Fanny Le Du, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 19, 2024
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patientsBarnabe Bouvarel, Oliver Colomban, Jean-Sebastien Frenel, et al.
Annals of Surgical Oncology|February 2, 2023
Comparison of Neoadjuvant Systemic Chemotherapy Protocols for the Curative-Intent Management of Peritoneal Metastases from Colorectal Cancer, Regarding Morphological Response, Pathological Response, and Long-Term Outcomes: A Retrospective StudyFlorian Fanget, Amaniel Kefleyesus, Julien Peron, et al.
Clinical Nuclear Medicine|May 23, 2024
Estimated Fetal Radiation Dose From 18 F-FDG PET/CT During the Second and Third Trimesters of PregnancyLaure Al Mansour, Perrine Tylski, Gautier Chene, et al.
Pageof 15